Infermedica Sp. z o.o.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Infermedica Sp. z o.o. - overview
Established
2012
Location
Wroclaw, -, Poland
Primary Industry
Software
About
Infermedica is a healthcare technology company specializing in AI-driven tools for symptom checking and virtual triage, aimed at enhancing patient care and operational efficiency in the healthcare sector. Founded in 2012 in Wroclaw, Poland, Infermedica Sp. z o. o.
develops healthcare solutions that streamline the patient assessment process. The company has raised a total of USD 30. 00 mn, with its most recent funding round being a Series B in January 2022 led by One Peak Partners, along with several returning investors. Piotr Orzechowski is the CEO, and the company was established by Irving Fccp and Roberto Sicconi.
Infermedica has completed a total of 9 deals to date. Infermedica offers a range of AI-powered healthcare solutions, with its flagship product being the Symptom Checker. This tool enables users to evaluate their symptoms and receive personalized guidance on care options. The company’s technology is integrated into various platforms, including websites and telemedicine services, and caters to a wide array of clients such as health plans and healthcare providers in over 32 countries.
Their offerings are available in 24 languages, optimizing patient engagement and operational efficiency while gathering essential health data. In the most recent fiscal year of 2023, Infermedica reported a revenue of USD 5,008,901. 30 and an EBITDA of USD 7,889,691. 10.
The company operates a revenue model based on subscription services and partnerships, allowing healthcare organizations to integrate their tools effectively into existing systems to improve patient care. Infermedica plans to leverage its recent Series B funding of USD 30. 00 mn raised in January 2022 to further its mission of making primary care efficient and affordable through advanced AI technologies. The funds will support the development of new products and enhance existing offerings.
The company is targeting expansion into key markets, particularly in North America and Asia, aiming to broaden its reach and impact by the end of 2024.
Current Investors
Unfold.vc, RTA Ventures, DreamIt Ventures
Primary Industry
Software
Sub Industries
Healthcare IT, Web Applications, Analytics & Performance Software, Medical Software
Website
www.infermedica.com
Verticals
Artificial Intelligence, HealthTech, Mobile Apps
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.